Post
Liberate Medical starts neuromuscular stimulator trial with $6.5m grant
Liberate Medical has commenced patient enrolment in a study investigating its neuromuscular electrical stimulator to help respiratory failure patients wean …
Replay wins IND clearance for PRAME T cell cancer therapy
Genome writing company Replay Bio has had its investigational new drug (IND) application cleared by the US Food and Drug …
ESCMID 2024: Cutting-edge vaccines in development for a healthier tomorrow
New vaccine trial data was presented during an oral session at the 34th European Society of Clinical Microbiology and Infectious …
ESCMID 2024: Highlights on prophylaxis and treatment of infectious diseases
At the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global (formerly ECCMID) conference in Barcelona, Spain, a …
Jemperli contends with blockbuster Keytruda in endometrial cancer
On April 24, the FDA granted Priority Review to the supplemental Biologics License Application (sBLA) for GSK’s Jemperli (dostarlimab) in …
Jemperli contends with blockbuster Keytruda in endometrial cancer
On April 24, the FDA granted Priority Review to the supplemental Biologics License Application (sBLA) for GSK’s Jemperli (dostarlimab) in …
ePRO vs eCOA: Understanding the nuances in clinical trials
Two such tools – electronic patient-reported outcomes (ePRO) and electronic clinical outcomes assessments (eCOA) – are often mentioned together. However, …
Genomics and GSK to integrate polygenic risk scores into trials
Genomics has entered a partnership with GSK to evaluate the potential integration of polygenic risk scores (PRS) into clinical trial …
Aurion Biotech concludes dosing in corneal oedema cell therapy trial
Aurion Biotech has announced the completion of dosing for all participants in the Phase I/II CLARA clinical trial of allogeneic …
Newron’s add-on schizophrenia therapy finds success in Phase II/III trial
Italian biopharma Newron Pharmaceuticals’s add-on schizophrenia treatment, evenamide, has met primary and secondary endpoints in a Phase II/III trial. The placebo-controlled …
Arsenal doses first subject in Phase I/II renal cell carcinoma trial
Arsenal Biosciences (ArsenalBio) has dosed the first subject in a Phase I/II clinical trial of AB-2100, a new therapy for …
Denovo Biopharma’s glioma gene therapy trial receives CIRM grant
Denovo Biopharma has secured an $11.8m grant from the California Institute for Regenerative Medicine (CIRM) in the US to conduct …
Trials to watch: Four ALS drugs to keep an eye on
It has been a turbulent few weeks for patients with amyotrophic lateral sclerosis (ALS) after Amylyx Pharmaceuticals pulled its lead …
Explainer: UK election 2024 – healthcare outlook
The United Kingdom is staring down the prospect of a general election, set to take place at some stage in …
Central nervous system remains most researched therapy area for DCTs
According to GlobalData’s Clinical Trials Database, the number of overall decentralised clinical trials (DCTs) has steadily increased from 282 trials …